Stratification and Partial Ascertainment of Biomarker Value in Biomarker-Driven Clinical Trials

Author：  

Publisher： Taylor & Francis Ltd

ISSN： 1054-3406

Source： Journal of Biopharmaceutical Statistics, Vol.24, Iss.5, 2014-09, pp. : 1011-1021

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A Pathway and Approach to Biomarker Validation and Qualification for Osteoarthritis Clinical Trials

By  

Current Drug Targets, Vol. 11, Iss. 5, 2010-05 ,pp. : 536-545

Bentham Science Publishers

Access to resources Recommend Favorite

The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria

By  

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3853-3858

Blackwell Publishing

Access to resources Recommend Favorite

Synergistic Approaches to Clinical Oncology Biomarker Discovery

By  

Current Topics in Medicinal Chemistry, Vol. 5, Iss. 11, 2005-09 ,pp. : 1047-1051

Bentham Science Publishers

Access to resources Recommend Favorite

Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications

By Cracowski J.-L.   Durand T.   Bessard G.  

Trends in Pharmacological Sciences, Vol. 23, Iss. 8, 2002-08 ,pp. : 360-366

Elsevier

Access to resources Recommend Favorite

Anti-Müllerian hormone: clinical insights into a promising biomarker of ovarian follicular status

By Feyereisen Estelle   Méndez Lozano Daniel H   Taieb Joëlle   Hesters Laetitia   Frydman René   Fanchin Renato  

Reproductive BioMedicine Online, Vol. 12, Iss. 6, 2006-06 ,pp. : 695-703

Reproductive Healthcare Ltd

Access to resources Recommend Favorite